Published in Medical Devices and Surgical Technology Week, October 19th, 2003
To "determine whether GO exposure prior to allogeneic SC transplantation increases the risk of developing VOD," M. Wadleigh and coauthors at the Dana-Farber Cancer Institute "conducted a retrospective study of 62 patients with previously treated AML/MDS (myelodysplastic syndrome) who underwent allogeneic stem cell (SC) transplantation at our institution from December...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.